tirzepatide cardiovascular risk compared with semaglutide and 10-year disease reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial Tirzepatide Associated with Lower Risk
Description
Two independent reviewers screened each study for eligibility at both the abstract and full text level
Semaglutide essentially amplifies this signal, helping you feel satisfied with smaller portions
Darsalia V, Ortster H, Olverling A, Darlf E, Wolbert P, Nystrm T, et al
The Proof Is in the Progress How long will it take to see results
Referral potential: Map primary care practices, endocrinologists, and bariatric surgeons who might refer patients to a medical weight loss program
